Spiriva and Lucentis make France's 100 most reimbursed list
This article was originally published in Scrip
Executive Summary
Just two years after its launch, Boehringer Ingelheim's Spiriva (tiotropium) for chronic obstructive pulmonary disease rose to 40th place last year in the French healthcare insurance programme's list of the top 100 drugs by reimbursement value. Novartis's Lucentis (ranibizumab) appeared in 96th place on the list in its first year of being marketed.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.